Difference between revisions of "Hand-foot syndrome (palmar-plantar erythrodysesthesia) management"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Doxorubicin liposomal (Doxil)" to "Pegylated liposomal doxorubicin (Doxil)")
m
Line 20: Line 20:
 
==References==
 
==References==
 
# Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. [http://www.ejoncologynursing.com/article/S1462-3889%2804%2900054-7/abstract link to original article] [http://www.roche.com.mx/fmfiles/re756001/wp/AttachedFile_04470.pdf PDF of paper at Roche.com] [https://www.ncbi.nlm.nih.gov/pubmed/15341880 PubMed]
 
# Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. [http://www.ejoncologynursing.com/article/S1462-3889%2804%2900054-7/abstract link to original article] [http://www.roche.com.mx/fmfiles/re756001/wp/AttachedFile_04470.pdf PDF of paper at Roche.com] [https://www.ncbi.nlm.nih.gov/pubmed/15341880 PubMed]
−
# Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008 Feb;108(2):332-5. [http://www.sciencedirect.com/science/article/pii/S0090825807008608 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18083217 PubMed]
+
# Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008 Feb;108(2):332-5. [https://www.gynecologiconcology-online.net/article/S0090-8258(07)00860-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18083217 PubMed]
−
# Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. doi: 10.1634/theoncologist.2008-0131. Epub 2008 Sep 8. [http://theoncologist.alphamedpress.org/content/13/9/1001.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18779536 PubMed]
+
# Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. Epub 2008 Sep 8. [http://theoncologist.alphamedpress.org/content/13/9/1001.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18779536 PubMed]
 
# Lacouture, ME. Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome. ASCO Post. December 15, 2012, Volume 3, Issue 18. [http://www.ascopost.com/issues/december-15-2012/prevention-and-treatment-of-multikinase-inhibitor%E2%80%93induced-hand-foot-syndrome.aspx link to original article]
 
# Lacouture, ME. Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome. ASCO Post. December 15, 2012, Volume 3, Issue 18. [http://www.ascopost.com/issues/december-15-2012/prevention-and-treatment-of-multikinase-inhibitor%E2%80%93induced-hand-foot-syndrome.aspx link to original article]
 
# [http://www.cancer.net/all-about-cancer/treating-cancer/managing-side-effects/hand-foot-syndrome-or-palmar-plantar-erythrodysesthesia Management/treatment of Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia (Cancer.net)]
 
# [http://www.cancer.net/all-about-cancer/treating-cancer/managing-side-effects/hand-foot-syndrome-or-palmar-plantar-erythrodysesthesia Management/treatment of Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia (Cancer.net)]

Revision as of 03:02, 17 August 2018

Associated with use of

Also known as

Acral erythema, Burgdorf's reaction, hand-foot skin reaction, hand-to-foot syndrome, PPE, toxic erythema of the palms and soles

References

  1. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. link to original article PDF of paper at Roche.com PubMed
  2. Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008 Feb;108(2):332-5. link to original article PubMed
  3. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. Epub 2008 Sep 8. link to original article PubMed
  4. Lacouture, ME. Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome. ASCO Post. December 15, 2012, Volume 3, Issue 18. link to original article
  5. Management/treatment of Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia (Cancer.net)
  6. Patient education about hand-foot syndrome (Chemocare.com)
  7. Cutaneous complications of conventional chemotherapy agents (uptodate.com)
  8. Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy (uptodate.com)
  9. Prevention and management of hand-foot syndromes (Oncologynurseadvisor.com)
Retrieved from "https://hemonc.org/w/index.php?title=Hand-foot_syndrome_(palmar-plantar_erythrodysesthesia)_management&oldid=30044"